Stryker stock: Truist cuts target to USD 310 for Stryker stock

Published on 10/23/2026 at 15:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Analysts see third-quarter revenue at USD 6.62 billion. Stryker stock costs EUR 273.85 on October 23, 2026, down 0.29 percent versus Xetra close.

Truist target cut and results date

Truist Financial cut its Stryker target from USD 340.00 to USD 310.00 on October 6, 2026.
Stryker is scheduled to report third-quarter results on October 29, 2026.
Stryker stock costs EUR 273.85 at Lang & Schwarz on October 23, 2026 at 3:34 p.m. CEST, down 0.29 percent versus the Xetra close.

3D-Architekturrender eines modernen verglasten Firmengebäudes mit klarer Fassade — Architektonisches 3D-Render eines modernen Glasgebäudes repräsentiert den Unternehmenssitz von Stryker Corp. US8636671013 im Medizintechnik-Bereich, Illustration mit AI erstellt.

Stryker Corp. stock (ISIN US8636671013) is facing a lower Truist Financial target after the firm cut its forecast from USD 340.00 to USD 310.00 on October 6, 2026, according to MarketBeat. The new target is 1.05 percent above the USD 306.77 NYSE price at 9:43 a.m. ET on October 23, 2026. At Lang & Schwarz, Stryker stock was trading at EUR 273.85 on October 23, 2026 at 3:34 p.m. CEST, down 0.29 percent versus the Xetra close of October 22, 2026 at EUR 274.65.

Truist target sets a lower hurdle

The Truist reduction is part of a broader sequence of target revisions ahead of Stryker's third-quarter report. The MarketBeat review also lists a USD 310.00 target and a Hold rating from Truist Financial, while Stryker's latest reported quarterly period delivered revenue of USD 6.59 billion and 9.40 percent year-over-year growth.

October 29 brings the next test

Stryker is scheduled to release third-quarter 2026 results after the market close on October 29, 2026, with a conference call at 4:30 p.m. ET. The company announcement, carried by Financial Times, says the accompanying release is planned for approximately 4:05 p.m. ET. MarketBeat cites consensus estimates of USD 6.62 billion in revenue and USD 3.55 in earnings per share.

Price position and valuation

The US-listed stock stood at USD 306.77 on October 23, 2026 at 9:43 a.m. ET, with a market capitalization of USD 117.7 billion and a price-to-earnings ratio of 31.84. Its 52-week range was USD 267.00 to USD 389.33, putting the price 21.13 percent above the low and 21.20 percent below the high. Trading volume was 76,240 shares at that time.

Comparison with peers

Stryker Corp. (NYSE, USD): down 0.29 percent versus the Xetra close, price-to-earnings ratio 31.84, market capitalization USD 117.7 billion.

Medtronic (NYSE, USD): down 0.10 percent on October 23, 2026, price-to-earnings ratio 23.80, market capitalization USD 123.4 billion.

Boston Scientific (NYSE, USD): down 0.52 percent on October 23, 2026, price-to-earnings ratio 18.65, market capitalization USD 66.3 billion.

What comes next for valuation

The October 29 release will put the USD 6.62 billion revenue estimate alongside Stryker's operating performance and the lower USD 310.00 target. The key comparison is whether reported growth can support a valuation above the peer ratios while the stock remains below its 52-week high.

Stock holds above its yearly low

At Lang & Schwarz, Stryker stock was trading at EUR 273.85 on October 23, 2026 at 3:34 p.m. CEST, down 0.29 percent versus the Xetra close of October 22, 2026 at EUR 274.65.

The further course of trading is shown by the continuously updated real-time quote of Stryker stock.